Australian research leads to clinical trial for rare women’s cancers

An international clinical trial exploring a new way to treat rare and aggressive gynecological cancers has launched in Melbourne, Australia

2023-09-22

(Press-News.org)

An international clinical trial exploring a new way to treat rare and aggressive gynaecological cancers has launched in Melbourne.

Based on a WEHI-led discovery, the trial hopes to enhance treatment options for women with two of the most lethal gynaecological cancers – ovarian and uterine carcinosarcomas.

The study will offer a novel combination therapy for women with these relapsing cancers and is now open in Australia, with plans to expand to Canada and the United Kingdom in coming months.

At a glance

New clinical trial launches in Melbourne to test a potential treatment for two aggressive and rare gynaecological cancers.

The trial, based on results from a WEHI-led study, will test a combination chemotherapy and immunotherapy treatment for women with recurrent ovarian and uterine carcinosarcomas.

Patient outcomes and treatment options for these diseases largely remain unchanged, highlighting a critical need for novel interventions.

In 2022, more than 1800 Australian women were diagnosed with ovarian cancer, including ovarian carcinosarcoma. Survival rates for ovarian cancer have not improved in over three decades, with one Australian woman dying from the disease every eight hours.

Uterine cancer was the fifth most diagnosed cancer in Australian females in 2022. Uterine carcinosarcoma, while three times more common than ovarian carcinosarcoma, is still classified as a rare cancer.

These diseases often present with no symptoms, meaning most women are diagnosed at an advanced stage – significantly limiting their treatment options.

The EPOCH (Eribulin and Pembrolizumab in Tubo-Ovarian and Uterine Carcinosarcoma) trial aims to reverse these dire outcomes by testing a new combination therapy. The study is funded by ANZGOG (Australia New Zealand Gynaecological Oncology Group) and developed via the International Gynecologic Cancer InterGroup.

Professor Clare Scott AM, Principal Investigator of the EPOCH trial and Chair of ANZGOG, said the trial could provide real hope for women with rare cancers.

“When a disease is rare, it means the research into it is much more challenging, halting the discovery of new treatments,” Prof Scott, also a Joint Division Head at WEHI’s Clinical Translation Division, said.

“Ovarian carcinosarcoma is currently treated with the same drugs used for the more common ovarian cancers, but these tumours generally respond poorly to standard-of-care treatments.

“This is proof that blanket approaches aren’t viable when it comes to rare cancers and that new treatments are desperately needed.

“That is why it is incredibly exciting to see our research, spanning over seven years, now translated into a clinical trial that could potentially help women living with rare diseases, like ovarian and uterine carcinosarcomas.”

Repurposed potential

EPOCH will give women with relapsing carcinosarcoma access to two treatments that have never been used for these cancers before.

The trial is based on findings from a WEHI study published in Cancer Research, which showed a chemotherapy drug used to treat advanced stages of breast cancer was more effective for ovarian carcinosarcoma than the most proven chemotherapy, platinum chemotherapy.

Using a variety of human ovarian carcinosarcoma pre-clinical models, the team investigated whether the chemotherapy drug Eribulin could be used to reverse a process associated with tumour progression and drug resistance, known as epithelial-to-mesenchymal transition (EMT).

Dr Holly Barker, who spearheaded the research, found the chemotherapy drug could reverse EMT in ovarian carcinosarcoma, reducing the growth and aggressive nature of these tumours.

“We found Eribulin specifically inhibited EMT, reducing cell invasion – which could minimise the likelihood of the tumour spreading,” Dr Barker said.

The team also found the drug boosted the immune response towards ovarian carcinosarcoma, as more immune cells were found in the tumours following treatment. This suggests Eribulin treatment could make these tumours more responsive to immunotherapy.

Early studies in uterine carcinosarcoma pre-clinical models, developed by the team, indicate Eribulin treatment is also more effective than platinum chemotherapy at reducing tumour growth for this type of cancer.

The EPOCH trial will test this dual effect by combining Eribulin with the immunotherapy drug, Pembrolizumab, for the first time.

“We hope the promising results we saw in our initial research will be emulated in the trial to improve outcomes for these women,” Dr Barker said.

Identifying ‘super responders’

As part of the trial, researchers will also search for biomarkers that can help identify the patients who will best respond to this combination therapy.

All patient samples from this trial will be analysed in Prof Scott’s WEHI lab by Anthony Hadla, a PhD student who is supported by a generous donation from Steve Tyerman.

EPOCH is one of the first ANZGOG trials to incorporate TR-ANZGOG (Translational ANZGOG), a program implemented to support the collection of biospecimens associated with ANZGOG trials and help facilitate current and future translational research.

The research underpinning this trial was supported by the Grant-in-Aid Scheme (jointly funded by Cancer Council Victoria and Ovarian Cancer Research Foundation), the Stafford Fox Medical Research Foundation, the Victorian Cancer Agency, the University of Melbourne, the Victorian Government and the Australian National Health and Medical Research Council. Drugs are being supplied by Eisai Co and Merck, Sharp and Dohme.

The EPOCH trial is now open at Melbourne’s Peter MacCallum Cancer Centre and Monash Health.

The first stage of the international trial aims to recruit 30 participants, with the recruitment of a further 60 participants planned for the second stage.

The trial will also expand to the following sites in coming months: Royal Brisbane and Women's Hospital (Queensland), Prince of Wales Hospital (New South Wales), Princess Margaret Cancer Centre (Canada), Imperial College (United Kingdom).

For more information about the EPOCH trial: https://www.anzgog.org.au/new-rare-gynaecological-cancer-study-epoch-opens-to-recruitment/

END

[Attachments] See images for this press release:

Australian research leads to clinical trial for rare women’s cancers 2

Australian research leads to clinical trial for rare women’s cancers 3

ELSE PRESS RELEASES FROM THIS DATE:

Newer diabetes treatments are understudied in Black populations and may be less beneficial

2023-09-22

New research analysing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations. Cardiovascular disease is the leading cause of severe illness and death associated with type 2 diabetes. Renal disease is also a common complication of type 2 diabetes. The drugs, called sodium-glucose co-transporter 2 inhibitors (SGLT2-Is) and glucogen-like peptide 1 receptor agonists (GLP1-RAs), are some of the newer treatments prescribed to lower blood sugar levels in people with type 2 diabetes. The research findings, published in the Journal of the ...

Ochsner offers tuition assistance to aspiring nurses and doctors

2023-09-22

NEW ORLEANS, LOUISIANA – Ochsner Health is again expanding its Ochsner Scholars program for aspiring nurses and physicians ready to fill critical healthcare shortages in local communities and shape the healthcare workforce of the future. Ochsner is excited to announce tuition assistance for 100 Nurse Scholars pursuing Associate Degree in Nursing (ADN), Licensed Nurse Practitioner (LPN), Bachelor of Science in Nursing (BSN) and Accelerated Bachelor of Science in Nursing (ABSN) degrees this spring to students across Louisiana and Mississippi. Ochsner is also covering tuition for up to 10 Physician Scholars ...

Colorful primates don’t have better color vision, study finds

2023-09-22

Primate species with better colour vision are not more likely to have red skin or fur colouration, as previously thought. The findings, published this week in the Biological Journal of the Linnean Society, suggest that red skin and/or red-orange fur may be beneficial for use in social communication even in primate species that don't have particularly good colour vision. It's long been assumed that primates' colourful skin and fur is linked to their enhanced colour vision, and the results may have implications for understanding why these traits exist in different species. Lead author Robert MacDonald from the University of Bristol explained: ...

Large-scale German study discovers earlier puberty onset in both girls and boys with diabetes

2023-09-22

Puberty in both girls and boys with type 1 diabetes has shifted forward over the last two decades, according to research presented at the 61st Annual European Society for Paediatric Endocrinology Meeting in The Hague. Additionally longer duration of diabetes, bigger waistlines, and lower blood sugar levels were associated with even earlier puberty onset. The findings of this large-scale study highlight a close relationship between type 1 diabetes and puberty onset and the utmost importance of managing diabetes and weight ...

Novel method reveals link between man-made chemicals in everyday products and later puberty

2023-09-22

Children exposed to higher levels of synthetic chemicals in everyday products, such as water-resistant clothes, umbrellas and food packaging, are more likely to mature later during puberty, according to research presented at the 61st Annual European Society for Paediatric Endocrinology Meeting in The Hague. The findings may help better regulate the industrial production and use of these chemicals on a national and international level. Perfluoroalkyl and polyfluoroalkyl substances (PFAS), also known ...

Benefit breakdown, 3D printed vs. wood molds

2023-09-21

Oak Ridge National Laboratory researchers have conducted a comprehensive life cycle, cost and carbon emissions analysis on 3D-printed molds for precast concrete and determined the method is economically beneficial compared to conventional wood molds. Precast concrete is used in building construction and produced by pouring the material into a reusable mold. For decades, these molds have been made from wood — a technique that requires a highly specialized skillset. As an alternative, molds made from fiber-reinforced polymer composites can be 3D printed. “We developed a techno-economic model that compared costs associated with each method, evaluating materials, equipment, ...

Peru’s Operation Mercury stopped most illegal gold mining in one biodiversity hotspot in the Amazon. Then the COVID-19 pandemic hit.

2023-09-21

Artisanal and small-scale gold mining is a lifeline for many who live in Madre de Dios, a region in southeastern Peru, where poverty is high and jobs are scarce. But the economic development in this part of the Amazon basin comes at a cost, as it causes deforestation, build up of sediment in rivers, and mercury contamination in nearby watersheds, threatening public health, Indigenous peoples, and the future of the biodiversity hotspot. And much of the mining activity is unauthorized. Seeking to eliminate illegal artisanal and small-scale gold mining activity and its many negative impacts, the Peruvian government deployed “Operation Mercury” (Operation Mercurio) in February ...

Texas A&M-led humanities project seeks to preserve an endangered language

2023-09-21

Texas A&M University historian Dr. Daniel Schwartz has devoted the last decade of his professional life to preserving the past — specifically, the culture of a 2,000-year-old language known as Syriac. He and likeminded colleagues from around the world have been working across place, time and cyberspace to safeguard Syriac cultural heritage, painstakingly creating Syriaca.org, a cyberinfrastructure to link Syriac literature to their persons, places, manuscripts and key concepts. This spring, they received another big assist from the National ...

Cancer Prevention and Research Institute of Texas awards $2 million grant to SMU

2023-09-21

DALLAS (SMU) – The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded $2 million to recruit Annika Wylie to SMU and fund five years of her research, which focuses on the p53 gene, a naturally occurring tumor suppressor. CPRIT is the state agency mandated to create and expedite innovation in the area of cancer research and enhance the potential for a medical or scientific breakthrough in both prevention and cures. CPRIT is now a $6 billion, 20-year initiative – the largest state cancer research investment ...

Study shows millions of people live with co-occuring chronic pain and mental health symptoms

2023-09-21

New University of Arizona Health Sciences research recently published in the journal PAIN found that nearly 1 in 20 adults in the U.S. experience the co-occurrence of chronic pain and anxiety or depression, resulting in functional limitations in daily life. Prior research has shown that chronic pain along with symptoms of anxiety or depression are biologically linked. This study is one of the few to examine the national prevalence of chronic pain with anxiety or depression symptoms in adults. The results shed light on the fact that millions ...